Rudolf Fleischmann

1959 University of Munich, München, Bayern, Germany 
"Rudolf Fleischmann"
Mean distance: 8.37
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Li H, Suwunnarat S, Fleischmann R, et al. (2017) Random Matrix Theory Approach to Chaotic Coherent Perfect Absorbers. Physical Review Letters. 118: 044101
Degueldre H, Metzger JJ, Schultheis E, et al. (2017) Channeling of Branched Flow in Weakly Scattering Anisotropic Media. Physical Review Letters. 118: 024301
Suwunnarat S, Li H, Fleischmann R, et al. (2016) Low-temperature linear thermal rectifiers based on Coriolis forces. Physical Review. E. 93: 042115
Hennig H, Neff T, Fleischmann R. (2016) Dynamical phase diagram of Gaussian wave packets in optical lattices. Physical Review. E. 93: 032219
Witcher J, Fleischmann R, Chindalore VL, et al. (2015) Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus. British Journal of Clinical Pharmacology
Pope J, Bingham CO, Fleischmann RM, et al. (2015) Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. Arthritis Research & Therapy. 17: 343
Cohen SB, Koenig A, Wang L, et al. (2015) Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III. Clinical and Experimental Rheumatology
Weinblatt ME, Fleischmann R, van Vollenhoven RF, et al. (2015) Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Research & Therapy. 17: 325
Strand V, Kremer J, Wallenstein G, et al. (2015) Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Research & Therapy. 17: 307
Mease P, Deodhar A, Fleischmann R, et al. (2015) Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. Rmd Open. 1: e000119
See more...